BMO Capital Maintains Outperform on Korro Bio, Maintains $120 Price Target
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Kostas Biliouris maintains an Outperform rating on Korro Bio (NASDAQ:KRRO) with a $120 price target.
May 15, 2024 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital analyst Kostas Biliouris maintains an Outperform rating on Korro Bio with a $120 price target.
The reaffirmation of an Outperform rating and a high price target of $120 by a reputable analyst is likely to positively influence investor sentiment and drive short-term price appreciation for Korro Bio.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100